NCT03393871

Brief Summary

The background for performing the present study is to compare the mass calculations by CT scanning and by invasive absolute blood flow measurements and thereby corroborating both methods.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Feb 2018

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 28, 2017

Completed
12 days until next milestone

First Posted

Study publicly available on registry

January 9, 2018

Completed
23 days until next milestone

Study Start

First participant enrolled

February 1, 2018

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2018

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2019

Completed
Last Updated

July 24, 2019

Status Verified

February 1, 2018

Enrollment Period

10 months

First QC Date

December 28, 2017

Last Update Submit

July 23, 2019

Conditions

Outcome Measures

Primary Outcomes (2)

  • Comparison of Mass and flow

    To compare relative myocardial mass distribution (i.e. mass of the respective territories of LAD, LCX and RCA) by CT scanning to normalized hyperemic blood flow in the three major myocardial territories as assessed by absolute flow measurements and FFR in patients with an indication for multivessel FFR measurement.

    3 months

  • Comparison of Mass and flow in the LAD

    To compare relative myocardial mass belonging to a proximal or a mid segment of one of the major coronary arteries measured by CT scanning to invasive absolute flow and FFR measurement in that particular proximal or mid coronary artery in patients undergoing single or multivessel PCI.

    3 months

Interventions

Absolute maximum flow will be measured, using the RayFlow® multifunctional monorail infusion catheter. (This measurement takes a few minutes per artery, does not require any additional drug, but only 50-100 ml of saline per artery, and is not associated with any additional risk for the patient compared to the regular invasive procedure.

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Sixty patients will be included who are scheduled 1. Either for multivessel FFR/PCI fulfilling the following criteria and not meeting any of the exclusion criteria (prospective group) 2. Or patients in whom both coronary CT scanning and invasive exams have been performed already for clinical reasons and of whom "complete data" are available already (retrospective group)

You may qualify if:

  • Presence of multivessel coronary disease with an indication for multivessel FFR and/or PCI or patients with single vessel disease scheduled for FFR/PCI of that single coronary artery
  • Availability of a coronary CT scan performed prior to the scheduled invasive investigation. The time difference between the CT scan and the invasive exam should be less than 3 months.
  • Focal lesions only
  • Normal left ventricular function
  • Age \< 75 years
  • Note: previous uncomplicated PCI in any of the coronary arteries is permitted

You may not qualify if:

  • Inability to give informed consent
  • Diffuse coronary disease
  • Tortuous or calcified arteries interfering with reliable invasive FFR assessment
  • Previous myocardial infarction or ejection fraction less than 60% by echocardiography or ventriculography or less than 50% by nuclear methods
  • Atrial fibrillation interfering with high quality coronary CT scanning
  • Contra-indications for CT scanning
  • Left main stenosis
  • Age \> 75 years
  • Pregnancy or desired pregnancy in the future

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Catharina Hospital

Eindhoven, North Brabant, 5623EJ, Netherlands

Location

MeSH Terms

Conditions

Coronary Artery Disease

Condition Hierarchy (Ancestors)

Coronary DiseaseMyocardial IschemiaHeart DiseasesCardiovascular DiseasesArteriosclerosisArterial Occlusive DiseasesVascular Diseases

Study Officials

  • Nico HJ Pijls, MD, PhD

    Catharina Ziekenhuis Eindhoven

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Dr. PHD

Study Record Dates

First Submitted

December 28, 2017

First Posted

January 9, 2018

Study Start

February 1, 2018

Primary Completion

December 1, 2018

Study Completion

March 1, 2019

Last Updated

July 24, 2019

Record last verified: 2018-02

Locations